Non-peptide angiotensin II type 1 receptor antagonist with selective partial peroxisome proliferator-activated receptor gamma agonism
A biphenyl-benzimidazole angiotensin II receptor blocker developed at Boehringer Ingelheim, distinguished from other sartans by intrinsic partial agonist activity at the nuclear peroxisome proliferator-activated receptor gamma and downstream metabolic, anti-inflammatory, and neuroprotective activity.
Abstract
Telmisartan is a non-peptide, orally active antagonist of the angiotensin II type 1 receptor (AT1R) and a selective partial agonist of the nuclear peroxisome proliferator-activated receptor gamma (PPARgamma), approved by the United States Food and Drug Administration in 1998 for the treatment of hypertension and subsequently for cardiovascular risk reduction in patients intolerant to angiotensin-converting enzyme inhibitors. The compound is marketed as Micardis (Boehringer Ingelheim) and is available in extensive generic competition worldwide. Among the eight clinically marketed angiotensin II receptor blockers (ARBs), telmisartan is distinguished by three pharmacological and pharmacokinetic features: the longest terminal elimination half-life (approximately 24 hours), the largest volume of distribution (approximately 500 liters), and a structurally defined partial agonist interaction with PPARgamma that is not shared at clinically meaningful potency by any other marketed sartan. These pleiotropic activities extend the pharmacological profile of telmisartan substantially beyond the hemodynamic consequences of AT1R blockade and have driven a preclinical and clinical research literature encompassing metabolic syndrome, type 2 diabetes prevention, neuroprotection, renoprotection, and anti-inflammatory applications.
The clinical evidence base for telmisartan is anchored by two landmark randomized controlled trials. The TRANSCEND trial (Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease; N = 5,926) demonstrated that telmisartan modestly reduced the composite of cardiovascular death, myocardial infarction, or stroke compared with placebo in ACE-inhibitor-intolerant patients, leading to the 2009 FDA supplemental indication for cardiovascular risk reduction [3]. Additional large-scale trials include PRoFESS (Prevention Regimen for Effectively Avoiding Second Strokes; N = 20,332), which evaluated telmisartan for secondary stroke prevention, and DETAIL (Diabetics Exposed to Telmisartan and Enalapril; N = 250), which demonstrated renoprotective non-inferiority to enalapril in type 2 diabetic patients with early nephropathy.
The compound is poorly soluble in water but freely soluble in dimethyl sulfoxide and dimethylformamide. Telmisartan does not require dose adjustment for renal impairment but should be used with caution in severe hepatic impairment owing to the predominantly biliary elimination pathway.
This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.